This morning, Array Biopharma will outline its plans to investors to get its first wholly-owned drug, a treatment for the blood cancer multiple myeloma, approved by the Food and Drug Administration.

Despite the attractive electrical properties and physical features of single-walled carbon nanotubes, incorporating them into scalable integrated circuits has proven to be a challenge because of ...

Every company has a journey and Sumeet Shrivastava shares with Editor Nick Wakeman the path Array Information Technologies followed from when he joined as CEO in 2008 to its recent sale to CGI Federal ...

Array Technologies (NASDAQ:ARRY) +2.6% in Wednesday's trading as Janney initiated coverage with a Buy rating and $37 price target, saying investment tax credits "provide a path to significant ...